欢迎访问《微生物与感染》官方网站,今天是
综述

解脲脲原体耐药性研究进展

  • 郭炽鹏 ,
  • 陆春 ,
  • 朱国兴
展开
  • 中山大学附属第三医院皮肤性病科,广州 510630

收稿日期: 2018-01-22

  网络出版日期: 2018-01-01

基金资助

广东省科技计划项目(2014A020213023)

Research progress on drug resistance of Ureaplasma urealyticum

  • GUO Chipeng ,
  • LU Chun ,
  • ZHU Guoxing
Expand
  • Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

Received date: 2018-01-22

  Online published: 2018-01-01

摘要

解脲脲原体是条件致病菌。目前对其耐药性的研究主要包括对喹诺酮类、大环内酯类和四环素类3种抗菌药物相关耐药突变位点的检测,以及生物膜对病原体相关药物敏感性的影响,研究方法和检验手段仍较为传统、局限,研究方案也仅停留在对前人实验的重复。近年来,有学者将多位点序列分型技术用于解脲脲原体耐药序列类型的研究。在完善耐药机制研究的基础上,如何实现对耐药株的快速鉴定,从而指导抗菌药物的合理选择等仍需进一步研究。

本文引用格式

郭炽鹏 , 陆春 , 朱国兴 . 解脲脲原体耐药性研究进展[J]. 微生物与感染, 2018 , 13(4) : 245 -249 . DOI: 10.3969/j.issn.1673-6184.2018.04.008

Abstract

Ureaplasma urealyticum (U. urealyticum) is an opportunistic pathogen. At present, the study of its resistance mechanisms mainly includes the detection of the related drug-resistance mutation sites for quinolones, macrolides and tetracyclines, and the influence of biofilm on the drug susceptibility. In recent years, some researchers have applied multilocus sequence typing (MLST) technology to explore the drug-resistance sequence types of U. urealyticum. Rapid identification of drug-resistant strains is an urgent clinical need for rational choice of antimicrobial agents.

文章导航

/